专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5773942A Power window motor driving apparatus 失效
标题翻译：电动窗马达驱动装置
公开(公告)号：US5773942A
公开(公告)日：1998-06-30
申请号：US651762
申请日：1996-05-22
申请人： Yoshiyuki Takahara , Tomohiro Iida
发明人： Yoshiyuki Takahara , Tomohiro Iida
IPC分类号： E05F15/16 , B60J1/17 , B60R16/02 , B60R16/03 , H04Q9/00 , H02P1/00
CPC分类号： B60R16/0315 , B60R2016/0322 , E05Y2400/504
摘要： A power window motor drive apparatus, which, in the event of data error of the external command data, from the driver's seat limits the generation of drive signals for the power window motor that are based on the internal command data internally generated by the operation of the window switch and on the external command data received from outside through the communications line. An external command data reference inhibit means is provided to inhibit only the generation of the drive signals based on the external command data.
摘要翻译：电动车窗马达驱动装置，在来自驾驶席的外部命令数据发生数据错误的情况下，限制基于内部命令数据生成的功率窗马达的驱动信号窗口开关和通过通信线路从外部接收到的外部命令数据。提供外部命令数据参考禁止装置，以仅基于外部命令数据来抑制驱动信号的产生。

2. 发明授权

US06806049B1 Method for analyzing gene expression frequency 失效
标题翻译：分析基因表达频率的方法
公开(公告)号：US06806049B1
公开(公告)日：2004-10-19
申请号：US09926028
申请日：2001-08-16
申请人： Takami Maekawa , Akira Mitsui , Masayo Date , Hisao Fukuda , Yoshiyuki Takahara
发明人： Takami Maekawa , Akira Mitsui , Masayo Date , Hisao Fukuda , Yoshiyuki Takahara
IPC分类号： C12Q168
CPC分类号： C12Q1/6809 , C12Q2525/191 , C12Q2521/313
摘要： In gene expression frequency analysis, a vector primer to which each cDNA is ligated is formed by synthesizing the cDNA from each mRNA using by a vector primer having a poly(T) sequence; each cDNA sequence is converted to a tag on the vector primer; a concatemer is formed by ligating the obtained tags via a sequence that enables recognition of ends of the tags; and the nucleotide sequence of the concatemer is analyzed.
摘要翻译：在基因表达频率分析中，通过使用具有聚（T）序列的载体引物合成来自每个mRNA的cDNA，形成连接有每个cDNA的载体引物; 将每个cDNA序列转化为载体引物上的标签; 通过使得能够识别标签的末端的序列结合所获得的标签来形成并行器; 并对该并发物的核苷酸序列进行分析。

3. 发明授权

US6084670A Particle analyzer and composite lens formed by integrally joining plural lens elements of different focal points 失效
公开(公告)号：US6084670A
公开(公告)日：2000-07-04
申请号：US38281
申请日：1998-03-11
申请人： Masao Yamazaki , Yutaka Nagai , Katsuhiro Tsuchiya , Yoshiyuki Takahara
发明人： Masao Yamazaki , Yutaka Nagai , Katsuhiro Tsuchiya , Yoshiyuki Takahara
IPC分类号： G01N15/02 , G01N15/14 , G01N21/00
CPC分类号： G01N15/1434 , G01N15/14 , G01N15/0211 , G01N2015/1447 , G01N2015/149 , G01N2021/4716 , Y10S425/808
摘要： A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

4. 发明授权

US5541088A Recombinant process of producing non-glycosylated B-cell defferentiation factor 失效
标题翻译：生产非糖基化B细胞分化因子的重组过程
公开(公告)号：US5541088A
公开(公告)日：1996-07-30
申请号：US309612
申请日：1994-09-21
申请人： Tadamitsu Kishimoto , Toshio Hirano , Hiroshi Matsui , Yoshiyuki Takahara , Yukio Akiyama , Akira Okano
发明人： Tadamitsu Kishimoto , Toshio Hirano , Hiroshi Matsui , Yoshiyuki Takahara , Yukio Akiyama , Akira Okano
IPC分类号： A61K38/00 , C07K14/54 , C07K14/55 , C12N1/21 , C12N15/24 , C12N15/70
CPC分类号： C07K14/54 , C07K14/5403 , C07K14/5412 , C07K14/55 , A61K38/00 , C07K2319/00 , C07K2319/02 , C07K2319/75 , Y10S514/885
摘要： A purified human B-cell differentiation factor (BCDF) which does not have a natural signal peptide attached to the N-terminal thereof, DNA encoding the BCDF, transformed cells containing such DNA, a process for producing and obtaining the BCDF, and compositions containing the BCDF are disclosed.
摘要翻译：不具有与其N-末端连接的天然信号肽的纯化人B细胞分化因子（BCDF），编码BCDF的DNA，含有该DNA的转化细胞，生成和获得BCDF的方法，以及含有 BCDF被披露。

5. 发明授权

US07189810B2 Polypeptides, use thereof and process for producing the same 失效
标题翻译：多肽，其用途及其制备方法
公开(公告)号：US07189810B2
公开(公告)日：2007-03-13
申请号：US10327995
申请日：2002-12-26
申请人： Takami Maekawa , Hisao Fukuda , Fumihiko Yokoya , Tomohisa Okutsu , Yoshiyuki Takahara
发明人： Takami Maekawa , Hisao Fukuda , Fumihiko Yokoya , Tomohisa Okutsu , Yoshiyuki Takahara
IPC分类号： C07K2/00 , G01N33/53 , C12P21/08
CPC分类号： C07K14/47 , Y10S435/975
摘要： An isolated polypeptide comprises the amino acid sequence of SEQ ID NO: 11, wherein the expression of said polypeptide is significant lower specifically in human livers with hepatitis compared with that in human health livers. The detection of said polypeptide expression in human liver can be used as a diagnosis for human hepatitis.
摘要翻译：分离的多肽包含SEQ ID NO：11的氨基酸序列，其中与人类健康肝脏相比，所述多肽的表达在具有肝炎的肝脏肝脏中特异性明显更低。人肝脏中所述多肽表达的检测可用作人类肝炎的诊断。

6. 发明授权

US6157500A Particle analyzer and composite lens formed by integrally joining plural lens elements of different focal points 有权
公开(公告)号：US6157500A
公开(公告)日：2000-12-05
申请号：US457390
申请日：1999-12-09
申请人： Masao Yamazaki , Yutaka Nagai , Katsuhiro Tsuchiya , Yoshiyuki Takahara
发明人： Masao Yamazaki , Yutaka Nagai , Katsuhiro Tsuchiya , Yoshiyuki Takahara
IPC分类号： G01N15/02 , G01N15/14 , G02C3/08 , F21V5/00
CPC分类号： G01N15/1434 , G01N15/14 , G01N15/0211 , G01N2015/1447 , G01N2015/149 , G01N2021/4716 , Y10S425/808
摘要： A flow cell 2, a composite lens 15, and first to third detectors 16 to 18 are arranged in this sequence in the light pathway of light emitted from a laser light source 1. The composite lens 15 is configured by a convex lens 15a, and lens elements 15b and 15c. These lenses have different focal lengths. When the posture of the composite lens is correct, light impinging on the convex lens forms an image on the first detector. Therefore, the positioning of the composite lens is enabled. When particles in the flow cell are irradiated with laser light, forward scatter is produced. Forward small angle scatter having a small scattering angle impinges on the first lens element 15b to be collected thereby, and is then received by the second detector 17. Forward large angle scatter having a large scattering angle impinges on the second lens element 15c in the outermost periphery to be collected thereby, and is then received by the third detector 18 which is remotest from the composite lens.

7. 发明授权

US5610284A Method of purification of human BCDF 失效
标题翻译：人BCDF纯化方法
公开(公告)号：US5610284A
公开(公告)日：1997-03-11
申请号：US275663
申请日：1994-07-15
申请人： Daisuke Ejima , Yutaka Sato , Mayumi Watanabe , Masayo Date , Yoshiyuki Takahara
发明人： Daisuke Ejima , Yutaka Sato , Mayumi Watanabe , Masayo Date , Yoshiyuki Takahara
IPC分类号： A61K38/00 , C07K14/54 , C07K1/14 , C12N15/19
CPC分类号： C07K14/5412 , A61K38/00
摘要： There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ion exchange chromatographic treatment and a reversed phase HPLC step, in combination (i) or (ii). According to these purification processes, it becomes possible to remove the impurities derived from a microorganism and human BCDF analogs, and the thus obtained natural type human BCDF has a high purity and can be utilized for pharmaceutical preparations.
摘要翻译：公开了（i）用于获得具有分子内二硫键的人BCDF和天然型人BCDF的立体结构的纯化方法，其包括进行氧化反应和重折叠处理，所述还原型人BCDF通过培养具有人BCDF基因整合在其中并用盐酸胍溶解，其特征在于，在氧化反应后，在盐酸胍浓度调节至4-7M的条件下进行凝胶过滤色谱处理; （ii）通过从含有机溶剂的人BCDF中除去有机溶剂来获得天然型人BCDF单体的纯化方法，其特征在于使溶液通过用有机溶剂平衡的凝胶过滤色谱柱，随后通过逐步或线性梯度程序洗脱; 和（iii）包含离子交换色谱处理和反相HPLC步骤（组合（i）或（ii））的人BCDF纯化方法。根据这些纯化方法，可以除去由微生物和人BCDF类似物衍生的杂质，由此得到的天然型人BCDF具有高纯度，可用于药物制剂。

8. 发明授权

US5441735A Method for controlling soft rot, bacterial seedling blight of rice and black rot 失效
标题翻译：控制软腐病，水稻和黑腐病细菌性枯萎病的方法
公开(公告)号：US5441735A
公开(公告)日：1995-08-15
申请号：US82675
申请日：1993-06-25
申请人： Yoshiyuki Takahara , Tetsuya Iwabuchi , Masayuki Shiota
发明人： Yoshiyuki Takahara , Tetsuya Iwabuchi , Masayuki Shiota
IPC分类号： A01N63/00 , A01C1/08 , C12M1/04 , C12N1/22
CPC分类号： C12R1/18 , A01N63/00
摘要： A microbial pesticide containing a living Erwinia carotovora subsp. carotovora, particularly, the Erwinia cartovora subsp. carotovora CGE234M403 strain, from which the pathogenicity of soft rot is deleted by mutagenesis and which is immobilized by mixing with a saccharide such as saccharose, glucose, fructose or sorbitol or beef extract and drying or freeze-drying the mixture under reduced pressure, as an active ingredient is applied to soil or plants, which are liable to suffer from soft rot, bacterial seedling blight of rice and black rot, in the form of a suspension, granules or powder to control the diseases.
摘要翻译：含有活的欧文氏菌的微生物农药 carotovora，特别是欧文氏菌Cartovora亚种。 carotovora CGE234M403菌株，其中软腐病的致病性通过诱变缺失，并通过与糖如蔗糖，葡萄糖，果糖或山梨醇或牛肉提取物混合而固定，并将该混合物在减压下干燥或冷冻干燥，作为活性成分施用于土壤或植物，其易于遭受软腐烂，水稻和黑腐病的细菌性幼苗枯萎，以悬浮液，颗粒或粉末的形式，以控制疾病。

9. 发明授权

US4294754A Ring peptide antibiotics, Permetin A and a process for producing the same 失效
标题翻译：环肽抗生素，Permetin A及其制备方法
公开(公告)号：US4294754A
公开(公告)日：1981-10-13
申请号：US27029
申请日：1979-04-04
申请人： Yoshiyuki Takahara , Yoshiteru Hirose , Yoko Takeuchi , Asao Murai , Masatsune Kainosho , Sawao Murao
发明人： Yoshiyuki Takahara , Yoshiteru Hirose , Yoko Takeuchi , Asao Murai , Masatsune Kainosho , Sawao Murao
IPC分类号： A61K35/74 , A61K38/00 , A61P31/04 , C07K7/06 , C07K11/00 , C07K11/02 , C07K14/195 , C07K14/41 , C12P21/04 , C07C103/52
CPC分类号： C07K7/06 , C12R1/09 , Y10S930/19 , Y10S930/27
摘要： A purified ring peptide antibiotic of the following empirical formula:N.alpha.-(3-hydroxy-4-methyl-1-oxohexyl)-L-.alpha.,.gamma.-diaminobutyryl-L-isoleucyl-L-.alpha.,.gamma.-diaminobutyryl-D-phenylalanyl-L-leucyl-L-.alpha.,.gamma.-diaminobutyryl-D-valyl-L-leucyl-L-serine (9-1)-lactoneand which has the following structural formula: ##STR1## and wherein Dab represents 2,4-diamino butyric acid.
摘要翻译：具有以下经验式的纯化的环肽抗生素：Nα-（3-羟基-4-甲基-1-氧代己基）-L-α，γ-二氨基丁酰基-L-异亮氨酰-L-α，γ-二氨基丁酰基-D- 苯丙氨酰-L-亮氨酰-L-α，γ-二氨基丁酰-D-缬氨酰-L-亮氨酰-L-丝氨酸（9-1） - 内酯，其具有以下结构式：其中Dab表示2,4 - 二氨基丁酸。

10. 发明授权

US08318781B2 G-protein-conjugated receptor agonist 失效
标题翻译： G蛋白偶联受体激动剂
公开(公告)号：US08318781B2
公开(公告)日：2012-11-27
申请号：US12597281
申请日：2008-04-25
申请人： Gozoh Tsujimoto , Akira Hirasawa , Naoki Miyata , Takayoshi Suzuki , Yoshiyuki Takahara , Masaji Ishiguro , Mie Hata
发明人： Gozoh Tsujimoto , Akira Hirasawa , Naoki Miyata , Takayoshi Suzuki , Yoshiyuki Takahara , Masaji Ishiguro , Mie Hata
IPC分类号： A01N43/40 , A01N43/78 , A01N37/12 , A01N37/44 , A01N43/00 , A61K31/445 , A61K31/425 , A61K31/33 , C07D213/72 , C07D213/78 , C07D277/82 , C07C63/00 , C07C65/00
CPC分类号： C07C311/51 , C07C217/18 , C07D213/74 , C07D215/12 , C07D257/04
摘要： Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R1 represents a C1-6 alkyl group or the like; R2 represents a hydrogen atom, a C1-4 alkyl group or a C1-4 alkoxy group; m and n independently represent an integer of 1 to 5; and X represents an oxygen atom, a sulfur atom or —NR3— [wherein R3 represents a hydrogen atom or a C1-4 alkyl group].
摘要翻译：公开了一种对GPR-120和/或GPR-40，特别是GPR-120具有激动作用的新的芳烷基羧酸化合物，因此可用作食欲调节剂，抗肥胖剂，糖尿病治疗剂，胰腺β分化细胞生长增强剂，代谢综合征治疗剂，胃肠道疾病治疗剂，神经病变治疗剂，精神障碍治疗剂，肺病治疗剂，治疗剂垂体激素分泌障碍或脂质调味剂/调味剂。芳烷基羧酸化合物由通式（I）表示。（I）其中环Q表示吡啶基等; R1表示C1-6烷基等; R2表示氢原子，C1-4烷基或C1-4烷氧基; m和n独立地表示1〜5的整数。 X表示氧原子，硫原子或-NR 3 - [其中R 3表示氢原子或C 1-4烷基]。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式